Oct. 16, 2026

Schizophrenia Gets an App and Your Dog Is Losing Sleep

Key Takeaways

The FDA has cleared Motivista as the first prescription digital therapeutic specifically targeted at treating the negative symptoms of schizophrenia in stable patients already on antipsychotics.
Data from the 16-week CONVOKE trial showed that the Motivista schizophrenia app provided a 2.6-point improvement edge over the control app.
The American College of Physicians released new guidance recommending menopausal hormone therapy as the first-line treatment for moderate to severe hot flashes and night sweats.
Recent healthcare technology research evaluated early feasibility data on medical AI chatbots taking pre-visit histories in urgent care settings.
Federal health authorities issued new recommendations regarding the safety risks associated with concentrated kratom products.

Show Notes

Friday, October 16, 2026

In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover the FDA clearance of Motivista as the first prescription app for negative symptoms of schizophrenia. They break down the 16 week CONVOKE trial and what a 2.6 point edge over a control app means for stable patients on antipsychotics. They also review new ACP guidance placing menopausal hormone therapy first for hot flashes and night sweats, with second and third line options. Plus: they discuss early feasibility data on a medical AI chatbot for pre visit histories, new federal recommendations on concentrated kratom products, and more.

Coverage Timeline:

(00:00) Intro

(01:08) Schizophrenia App Cleared

(03:50) Hot Flashes Guidance

(04:47) Dogs & Sleep Study

(06:51) AI In Urgent Care

(08:37) Awards & Dahlias

Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.

Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources

Medlines is a Human Content Production

Frequently Asked Questions

What is the Motivista schizophrenia app?

Motivista is the first FDA-cleared prescription digital therapeutic designed to help manage the negative symptoms of schizophrenia for stable patients undergoing antipsychotic treatment.

What did the CONVOKE trial show about the Motivista schizophrenia app?

The 16-week CONVOKE trial demonstrated that the Motivista app achieved a 2.6-point efficacy edge over a control app in stable patients with schizophrenia.

What is the new ACP guidance for hot flashes and night sweats?

The American College of Physicians now places menopausal hormone therapy as the first-line option for treating vasomotor symptoms like hot flashes and night sweats, followed by specific second- and third-line alternatives.